loading...| Preferred Name |
Axitinib |
|
| Synonyms |
|
|
| Definitions |
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C38718 |
|
| ALT_DEFINITION |
A substance that is being studied in the treatment of cancer. It belongs to the families of drugs called angiogenesis inhibitors and protein tyrosine kinase inhibitors. |
|
| CAS_Registry |
319460-85-0 |
|
| Chemical_Formula |
C22H18N4OS |
|
| code |
C38718 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. |
|
| Display_Name |
Axitinib |
|
| FDA_UNII_Code |
C9LVQ0YUXG |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Axitinib |
|
| Legacy Concept Name |
AG-013736 |
|
| Maps_To |
Axitinib |
|
| NCI_Drug_Dictionary_ID |
352181 |
|
| PDQ_Closed_Trial_Search_ID |
352181 |
|
| PDQ_Open_Trial_Search_ID |
352181 |
|
| Preferred_Name |
Axitinib |
|
| prefixIRI |
NCIT:C38718 |
|
| prefLabel |
Axitinib |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C1700874 |
|
| subClassOf |
http://purl.obolibrary.org/obo/NCIT_C93259 |